Literature DB >> 34528173

Recovery of Latent HIV-1 from Brain Tissue by Adoptive Cell Transfer in Virally Suppressed Humanized Mice.

Hang Su1, Sruthi Sravanam1, Brady Sillman1, Emiko Waight1, Edward Makarov1, Saumi Mathews1, Larisa Y Poluektova1, Santhi Gorantla1, Howard E Gendelman1,2, Prasanta K Dash3.   

Abstract

Defining the latent human immunodeficiency virus type 1 (HIV-1) burden in the human brain during progressive infection is limited by sample access. Human hematopoietic stem cells (hu-HSCs)-reconstituted humanized mice provide an opportunity for this study. The model mimics, in measure, HIV-1 pathophysiology, transmission, treatment, and elimination in an infected human host. However, to date, brain HIV-1 latency in hu-HSC mice during suppressive antiretroviral therapy (ART) was not studied. To address this need, hu-HSC mice were administered long acting (LA) ART 14 days after HIV-1 infection was established. Animals were maintained under suppressive ART for 3 months, at which time HIV-1 infection was detected at low levels in brain tissue by droplet digital polymerase chain reaction (ddPCR) test on DNA. Notably, adoptive transfer of cells acquired from the hu-HSC mouse brains and placed into naive hu-HSC mice demonstrated viral recovery. These proof-of-concept results demonstrate replication-competent HIV-1 reservoir can be established in hu-HSC mouse brains that persists during long-term ART treatment. Hu-HSC mice-based mouse viral outgrowth assay (hu-MVOA) serves as a sensitive tool to interrogate latent HIV-1 brain reservoirs.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adoptive transfer; Brain; Human immunodeficiency virus type one (HIV-1); Humanized mice; Latent virus recovery; Mouse viral outgrowth assay

Mesh:

Year:  2021        PMID: 34528173      PMCID: PMC8714687          DOI: 10.1007/s11481-021-10011-w

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  39 in total

1.  HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment.

Authors:  Deanna Saylor; Alex M Dickens; Ned Sacktor; Norman Haughey; Barbara Slusher; Mikhail Pletnikov; Joseph L Mankowski; Amanda Brown; David J Volsky; Justin C McArthur
Journal:  Nat Rev Neurol       Date:  2016-04-15       Impact factor: 42.937

Review 2.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice.

Authors:  Santhi Gorantla; Hannah Sneller; Lisa Walters; John G Sharp; Samuel J Pirruccello; John T West; Charles Wood; Stephen Dewhurst; Howard E Gendelman; Larisa Poluektova
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

4.  Initiation of HAART during acute simian immunodeficiency virus infection rapidly controls virus replication in the CNS by enhancing immune activity and preserving protective immune responses.

Authors:  David R Graham; Lucio Gama; Suzanne E Queen; Ming Li; Angela K Brice; Kathleen M Kelly; Joseph L Mankowski; Janice E Clements; M Christine Zink
Journal:  J Neurovirol       Date:  2010-12-07       Impact factor: 2.643

Review 5.  Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.

Authors:  Suzi Hong; William A Banks
Journal:  Brain Behav Immun       Date:  2014-10-22       Impact factor: 7.217

6.  Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis.

Authors:  Santhi Gorantla; Edward Makarov; Jennifer Finke-Dwyer; Antonio Castanedo; Adelina Holguin; Catherine L Gebhart; Howard E Gendelman; Larisa Poluektova
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

7.  Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques.

Authors:  Lucio Gama; Celina M Abreu; Erin N Shirk; Sarah L Price; Ming Li; Greg M Laird; Kelly A Metcalf Pate; Stephen W Wietgrefe; Shelby L O'Connor; Luiz Pianowski; Ashley T Haase; Carine Van Lint; Robert F Siliciano; Janice E Clements
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

8.  Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice.

Authors:  Hang Su; Yan Cheng; Sruthi Sravanam; Saumi Mathews; Santhi Gorantla; Larisa Y Poluektova; Prasanta K Dash; Howard E Gendelman
Journal:  Front Immunol       Date:  2019-02-28       Impact factor: 7.561

9.  Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

Authors:  Ya-Chi Ho; Liang Shan; Nina N Hosmane; Jeffrey Wang; Sarah B Laskey; Daniel I S Rosenbloom; Jun Lai; Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  Cell       Date:  2013-10-24       Impact factor: 41.582

10.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Authors:  Timothy J Henrich; Hiroyu Hatano; Oliver Bacon; Louise E Hogan; Rachel Rutishauser; Alison Hill; Mary F Kearney; Elizabeth M Anderson; Susan P Buchbinder; Stephanie E Cohen; Mohamed Abdel-Mohsen; Christopher W Pohlmeyer; Remi Fromentin; Rebecca Hoh; Albert Y Liu; Joseph M McCune; Jonathan Spindler; Kelly Metcalf-Pate; Kristen S Hobbs; Cassandra Thanh; Erica A Gibson; Daniel R Kuritzkes; Robert F Siliciano; Richard W Price; Douglas D Richman; Nicolas Chomont; Janet D Siliciano; John W Mellors; Steven A Yukl; Joel N Blankson; Teri Liegler; Steven G Deeks
Journal:  PLoS Med       Date:  2017-11-07       Impact factor: 11.069

View more
  1 in total

Review 1.  Novel Nanotechnology-Based Approaches for Targeting HIV Reservoirs.

Authors:  Leila Fotooh Abadi; Fouad Damiri; Mehrukh Zehravi; Rohit Joshi; Rohan Pai; Mohammed Berrada; Ehab El Sayed Massoud; Md Habibur Rahman; Satish Rojekar; Simona Cavalu
Journal:  Polymers (Basel)       Date:  2022-07-29       Impact factor: 4.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.